Cargando…

Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia

BACKGROUND: The antitumor drug nilotinib has a large inter- and intra individual variability in pharmacokinetics. Adherence to treatment may substantially influence plasma levels and has been recognized as the most important determinant of treatment failure in chronic myeloid leukemia (CML). A bette...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boons, Christel CLM, Swart, Eleonora L, Timmers, Lonneke, van de Ven, Peter M, Janssen, Jeroen JWM, Hugtenburg, Jacqueline G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991921/ https://www.ncbi.nlm.nih.gov/pubmed/24712728 http://dx.doi.org/10.1186/1471-2407-14-247

Ejemplares similares

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

The use of capecitabine in daily practice: a study on adherence and patients’ experiences
por: Timmers, Lonneke, et al.
Publicado: (2012)

The use of erlotinib in daily practice: a study on adherence and patients' experiences
por: Timmers, Lonneke, et al.
Publicado: (2011)

Food‐effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer
por: Timmers, Lonneke, et al.
Publicado: (2015)

Patient satisfaction with information on oral anticancer agent use
por: Boons, Christel C. L. M., et al.
Publicado: (2017)

Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice
por: Timmers, Lonneke, et al.
Publicado: (2016)

Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists
por: Timmers, Lonneke, et al.
Publicado: (2017)

Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study
por: En‐nasery ‐ de Heer, Selma, et al.
Publicado: (2022)

Effectiveness of a Patient-Tailored, Pharmacist-Led Intervention Program to Enhance Adherence to Antihypertensive Medication: The CATI Study
por: van der Laan, Danielle M., et al.
Publicado: (2018)

The (cost-)effectiveness of a patient-tailored intervention programme to enhance adherence to antihypertensive medication in community pharmacies: study protocol of a randomised controlled trial
por: van der Laan, Danielle M., et al.
Publicado: (2017)

Implementation fidelity of an intervention programme to enhance adherence to antihypertensive medication in Dutch community pharmacies
por: van der Laan, Danielle M., et al.
Publicado: (2019)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib
por: Takahashi, Naoto, et al.
Publicado: (2014)

Factors Associated With Nonadherence to Cardiovascular Medications: A Cross-sectional Study
por: van der Laan, Danielle M., et al.
Publicado: (2019)

Paul Rand /
por: Heller, Steven
Publicado: (2000)

The Cost-Effectiveness of an Intervention Program to Enhance Adherence to Antihypertensive Medication in Comparison With Usual Care in Community Pharmacies
por: Bosmans, Judith E., et al.
Publicado: (2019)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions
por: Hugtenburg, Jacqueline G, et al.
Publicado: (2013)

Autologous Stem Cell Transplantation in elderly Acute Myeloid Leukemia
por: Ossenkoppele, Gert J, et al.
Publicado: (2013)

The impact of cardiovascular medication use on patients’ daily lives: a cross-sectional study
por: van der Laan, Danielle M., et al.
Publicado: (2018)

The passion of Ayn Rand /
por: Branden, Barbara
Publicado: (1986)

Dr. John Rand
Publicado: (1912)

Rand’s Medical Chemistry
Publicado: (1855)

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
por: DeRemer, David L, et al.
Publicado: (2011)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
por: Jabbour, Elias, et al.
Publicado: (2010)

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia
por: Al-Jafar, Hassan A., et al.
Publicado: (2015)

Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice
por: Santoleri, Fiorenzo, et al.
Publicado: (2013)

A Retrospective Cohort Study of Upfront Nilotinib in Chronic Myeloid Leukemia: A Single-Center Experience
por: Singh, Reema, et al.
Publicado: (2021)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Rand Doctor's Distressing Death
Publicado: (1920)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
por: Piccaluga, Pier Paolo, et al.
Publicado: (2012)

PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells
por: Drube, Julia, et al.
Publicado: (2018)

Nilotinib-Induced Acute Pancreatitis in a Patient with Chronic Myeloid Leukemia
por: Patel, Vihang, et al.
Publicado: (2017)

Vasospastic angina in a chronic myeloid leukemia patient treated with nilotinib
por: Maruta, Shunsuke, et al.
Publicado: (2021)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
por: Carracedo, Miguel, et al.
Publicado: (2020)

Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method
por: van Leeuwen, Roelof WF, et al.
Publicado: (2010)

A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis
por: Paramarta, Jacqueline E., et al.
Publicado: (2016)

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
por: Hochhaus, Andreas, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jcbm36imb5di0hc1u91cqqebea